GLP-1 is a peptide secreted by L-type enteroendocrine cells in the ileum and colon in response to different nutrients, mainly glucose and lipids, whereas glucose-dependent insulinotropic polypeptide is produced by K cells present in the duodenum and the first portion of the jejunum
These additions do not change the sublingual administration technique but may slightly alter the taste of the drops
Moreover, treatment with GLP-1 resulted in a decrease of lipopolysaccharide (LPS)-induced activation of the BV-2 microglial cell line, accompanied by a decrease in TNF- secretion [63]
Its part of a group of treatments called peptide therapy, which can be really effective for people struggling with weight and other health issues
[6] [15] Gallbladder disease, including cholelithiasis and cholecystitis, occurs more frequently with rapid weight loss
Its action on these three receptors suggests a complementary mechanism where glucagon-induced gluconeogenesis is inhibited by GLP-1/GIP, and glucagons enhancement of energy expenditure is augmented by the appetite-suppressing effects of GLP-1/GIP, thereby promoting weight loss [112]
